Human B-cell receptor specific for H5 hemagglutinin and N1 neuraminidase (H5/N1 BCR)

Human B-cell receptors (BCRs) specific for H5 hemagglutinin (HA) and N1 neuraminidase (NA) are specialized transmembrane proteins on B lymphocytes that recognize H5N1 influenza antigens (Janeway et al., 2017). These receptors are composed of a membrane-bound immunoglobulin and a signal-transducing heterodimer (Ig-alpha/Ig-beta) (PMID: 29343439). Upon binding to H5 HA or N1 NA, the BCR initiates intracellular signaling pathways that lead to B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells (PMID: 29343439). HA-specific BCRs often target the conserved stem region, which is a key site for broadly neutralizing antibodies such as CR6261 and F10 (PMID: 19079604, PMID: 19246616). NA-specific BCRs target the neuraminidase enzyme, preventing the release of viral progeny from host cells (PMID: 25855244). These receptors are the primary targets for H5N1 vaccines, which aim to elicit protective humoral immunity (PMID: 30104475). They also serve as the source for therapeutic monoclonal antibodies like MEDI8852 (PMID: 27058958). Understanding the specificity and diversity of these BCRs is essential for developing universal influenza vaccines and managing pandemic threats (PMID: 21666135).

Other names

H5N1-specific B-cell receptorAnti-H5 HA BCRAnti-N1 NA BCRInfluenza A H5N1-specific BCRH5N1-neutralizing B-cell receptor

Antigen-mediated activation of B-cell receptors leads to clonal expansion, affinity maturation, and differentiation into antibody-secreting plasma cells and memory B cells (PMID: 29343439). Vaccines act as agonists to stimulate this process, while monoclonal antibodies derived from these receptors neutralize the virus by blocking entry or release (PMID: 19246616, PMID: 25855244).